Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases

Colorectal Cancer Clinical Trial

Official title:

Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03189576
• Other study ID #: ETL R15085
• Status: Active, not recruiting
• Phase: N/A
• Start date: October 1, 2015
• Est. completion date: August 30, 2023

Study information

• Verified date: May 2023
• Source: Tampere University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Circulating tumour DNA (ctDNA) is a promising tool when monitoring the residual disease in colorectal cancer (CRC). Current staging procedures are insufficient to identify the patient cohort at high risk, who might benefit from additional adjuvant therapy. We will show that the assessment of ctDNA is a non-invasive approach and easily taken at different time points via simple blood draw to monitor residual disease from the colorectal cancer patients after primary surgery. Minimal residual disease could be used in the future for individualized treatment decisions after primary surgery.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 37
• Est. completion date: August 30, 2023
• Est. primary completion date: August 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• planned colorectal primary surgery

Exclusion Criteria:

• unfit patients with dementia

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms
• Neoplasm, Residual
• Residual Disease

Intervention

Diagnostic Test:
• blood draw

Locations

Country	Name	City	State
Finland	Tampere University Hospital	Tampere

Sponsors (1)

Lead Sponsor	Collaborator
Tampere University Hospital

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ctDNA level	residual disease measured by sequential blood draws	3-6 months